XML 29 R24.htm IDEA: XBRL DOCUMENT v3.3.0.814

License and Collaboration Agreements - Additional Information (Detail) - USD ($)	3 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Mar. 31, 2013	Jun. 30, 2011	Jun. 30, 2015	Dec. 31, 2014
Collaborative Agreements And Contracts [Line Items]
Milestone payment received upon an FDA approval of ILUVIEN						$ 25,000,000
Collaborative research and development revenue	$ 180,000	$ 25,081,000
Current portion of deferred revenue	33,000				$ 33,000
Deferred revenue, less current portion	$ 5,587,000				5,596,000
Percentage of outstanding share capital owned by Pfizer	6.30%
Royalty income	$ 286,000	226,000
Accounts receivable	$ 569,000				622,000
Enigma Therapeutics Limited [Member]
Collaborative Agreements And Contracts [Line Items]
Percentage of royalties received from sublicense	8.00%
Percentage of non-royalty consideration received from sublicense	20.00%
Collaborative research and development revenue	$ 0	0
License agreement commencement date	2012-12
Upfront payment			$ 100,000
Annual license maintenance fee	$ 100,000
Deferred revenue	$ 0
Alimera [Member]
Collaborative Agreements And Contracts [Line Items]
Percentage of company's share of net profits	20.00%
Pre-profitability net losses percentage	20.00%
Maximum Percentage offset of previously incurred and unapplied pre-profitability quarterly net losses	4.00%
Percentage of net profit share after offset of previously incurred and unapplied pre-profitability net losses	16.00%
Percentage of royalties received from sublicense	20.00%
Percentage of non-royalty consideration received from sublicense	33.00%
Milestone payment received upon an FDA approval of ILUVIEN		25,000,000
Collaborative research and development revenue	$ 163,000	25,000,000
Non-royalty consideration received from sublicense	157,000
Pfizer Collaboration Agreement [Member]
Collaborative Agreements And Contracts [Line Items]
Collaborative research and development revenue	$ 0	0
Upfront payment				$ 2,300,000
Contingent option exercise period	90 days
License option upfront payment upon exercise	$ 20,000,000
Estimated selling price of the deliverables for revenue recognition				$ 6,700,000
Current portion of deferred revenue	0				0
Deferred revenue, less current portion	5,600,000				5,600,000
Bausch and Lomb [Member]
Collaborative Agreements And Contracts [Line Items]
Royalty income	286,000	226,000
Accounts receivable	295,000				$ 371,000
Evaluation Agreements [Member]
Collaborative Agreements And Contracts [Line Items]
Collaborative research and development revenue	$ 8,000	$ 35,000

X

- Definition

Annual license maintenance fee.

+ References

No definition available.

+ Details

Name:	psdv_AnnualLicenseMaintenanceFee
Namespace Prefix:	psdv_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

X

- Definition

Collaboration agreement ownership percentage in company.

+ References

No definition available.

+ Details

Name:	psdv_CollaborationAgreementOwnershipPercentageInCompany
Namespace Prefix:	psdv_
Data Type:	num:percentItemType
Balance Type:	na
Period Type:	instant

X

- Definition

Collaborative Agreements And Contracts [Line Items]

+ References

No definition available.

+ Details

Name:	psdv_CollaborativeAgreementsAndContractsLineItems
Namespace Prefix:	psdv_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Dependent upon the outcome of the development program, this is the option exercise period.

+ References

No definition available.

+ Details

Name:	psdv_FinalReportDemonstratingProofOfConceptLicenseOptionExercisePeriod
Namespace Prefix:	psdv_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

X

- Definition

License Agreement Start Year Month

+ References

No definition available.

+ Details

Name:	psdv_LicenseAgreementStartYearMonth
Namespace Prefix:	psdv_
Data Type:	xbrli:gYearMonthItemType
Balance Type:	na
Period Type:	duration

X

- Definition

License Option Exercise Upfront Payment

+ References

No definition available.

+ Details

Name:	psdv_LicenseOptionExerciseUpfrontPayment
Namespace Prefix:	psdv_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

X

- Definition

Maximum percentage of quarterly profit sharing offset by previously incurred and unapplied pre profitability net losses.

+ References

No definition available.

+ Details

Name:	psdv_MaximumPercentageOfQuarterlyProfitSharingOffsetByPreviouslyIncurredAndUnappliedPreProfitabilityNetLosses
Namespace Prefix:	psdv_
Data Type:	num:percentItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Milestone Payment Received Upon FDA Approval

+ References

No definition available.

+ Details

Name:	psdv_MilestonePaymentReceivedUponFdaApproval
Namespace Prefix:	psdv_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

X

- Definition

Non royalty consideration earned.

+ References

No definition available.

+ Details

Name:	psdv_NonRoyaltyConsiderationEarned
Namespace Prefix:	psdv_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

X

- Definition

Non royalty consideration percentage.

+ References

No definition available.

+ Details

Name:	psdv_NonRoyaltyConsiderationPercentage
Namespace Prefix:	psdv_
Data Type:	num:percentItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Profit Sharing on Sale of Product Minimum Percentage After Maximum Allowable Offset of Previously Incurred And Unapplied Pre Profitability Net Losses

+ References

No definition available.

+ Details

Name:	psdv_ProfitSharingOnSaleOfProductMinimumPercentageAfterMaximumAllowableOffsetOfPreviouslyIncurredAndUnappliedPreProfitabilityNetLosses
Namespace Prefix:	psdv_
Data Type:	num:percentItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Profit sharing on sale of product percentage.

+ References

No definition available.

+ Details

Name:	psdv_ProfitSharingOnSaleOfProductPercentage
Namespace Prefix:	psdv_
Data Type:	num:percentItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Royalty rate percentage.

+ References

No definition available.

+ Details

Name:	psdv_RoyaltyRatePercentage
Namespace Prefix:	psdv_
Data Type:	num:percentItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Share percentage of pre-profitability net losses on sale of product.

+ References

No definition available.

+ Details

Name:	psdv_SharePercentageOfPreProfitabilityNetLossesOnSaleOfProduct
Namespace Prefix:	psdv_
Data Type:	num:percentItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Upfront cash payment.

+ References

No definition available.

+ Details

Name:	psdv_UpfrontCashPayment
Namespace Prefix:	psdv_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

X

- Definition

Upfront Cash Payment Received Under Collaboration Agreement

+ References

No definition available.

+ Details

Name:	psdv_UpfrontCashPaymentReceivedUnderCollaborationAgreement
Namespace Prefix:	psdv_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

X

- Definition

Amount due from customers, clients, or other third-parties, or arising from transactions not separately disclosed, within one year of the balance sheet date (or the normal operating cycle, whichever is longer), net of allowances established for the purpose of reducing such receivables to an amount that approximates their net realizable value.

+ References

No definition available.

+ Details

Name:	us-gaap_AccountsAndOtherReceivablesNetCurrent
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

X

- Definition

Amount of deferred revenue as of balance sheet date. Deferred revenue represents collections of cash or other assets related to a revenue producing activity for which revenue has not yet been recognized. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef



-Publisher FASB



-Name Accounting Standards Codification



-Topic 605



-SubTopic 10



-Section S99



-Paragraph 1



-Subparagraph (SAB TOPIC 13.A.4(a).Q1 Response)



-URI http://asc.fasb.org/extlink&oid=27012821&loc=d3e214044-122780



Reference 2: http://www.xbrl.org/2003/role/presentationRef



-Publisher SEC



-Name Staff Accounting Bulletin (SAB)



-Number Topic 13



-Section A

+ Details

Name:	us-gaap_DeferredRevenue
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

X

- Definition

The carrying amount of consideration received or receivable as of the balance sheet date on potential earnings that were not recognized as revenue in conformity with GAAP, and which are expected to be recognized as such within one year or the normal operating cycle, if longer, including sales, license fees, and royalties, but excluding interest income.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef



-Publisher FASB



-Name Accounting Standards Codification



-Topic 210



-SubTopic 10



-Section 45



-Paragraph 8



-Subparagraph (b)



-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6935-107765



Reference 2: http://www.xbrl.org/2003/role/presentationRef



-Publisher FASB



-Name Accounting Standards Codification



-Topic 605



-SubTopic 10



-Section S99



-Paragraph 1



-Subparagraph (SAB TOPIC 13.A.4(a).Q1)



-URI http://asc.fasb.org/extlink&oid=27012821&loc=d3e214044-122780



Reference 3: http://www.xbrl.org/2003/role/presentationRef



-Publisher SEC



-Name Staff Accounting Bulletin (SAB)



-Number Topic 13



-Section A

+ Details

Name:	us-gaap_DeferredRevenueCurrent
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

X

- Definition

The noncurrent portion of deferred revenue amount as of balance sheet date. Deferred revenue is a liability related to a revenue producing activity for which revenue has not yet been recognized, and is not expected to be recognized in the next twelve months. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef



-Publisher FASB



-Name Accounting Standards Codification



-Topic 210



-SubTopic 10



-Section 45



-Paragraph 8



-Subparagraph (b)



-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6935-107765



Reference 2: http://www.xbrl.org/2003/role/presentationRef



-Publisher FASB



-Name Accounting Standards Codification



-Topic 605



-SubTopic 10



-Section S99



-Paragraph 1



-Subparagraph (SAB TOPIC 13.A.4(a).Q1)



-URI http://asc.fasb.org/extlink&oid=27012821&loc=d3e214044-122780



Reference 3: http://www.xbrl.org/2003/role/presentationRef



-Publisher SEC



-Name Staff Accounting Bulletin (SAB)



-Number Topic 13



-Section A

+ Details

Name:	us-gaap_DeferredRevenueNoncurrent
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

X

- Definition

Revenue from multiple-deliverable arrangements that include licensing fees and services revenue. Licensing revenue is consideration received from another party for the right to use, but not own, certain of the entity's intangible assets. Licensing arrangements include, but are not limited to, rights to use a patent, copyright, technology, manufacturing process, software or trademark. Licensing fees are generally, but not always, fixed as to amount and not dependent upon the revenue generated by the licensing party. An entity may receive licensing fees for licenses that also generate royalty payments to the entity. Services revenue may be derived by providing other, nonspecified, services during the reporting period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef



-Publisher FASB



-Name Accounting Standards Codification



-Topic 225



-SubTopic 10



-Section S99



-Paragraph 2



-Subparagraph (SX 210.5-03.1(d),(e))



-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

+ Details

Name:	us-gaap_LicenseAndServicesRevenue
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

X

- Definition

Represents the value established as the selling price of the significant unit of accounting used to allocate the consideration of the multiple-deliverable arrangement.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef



-Publisher FASB



-Name Accounting Standards Codification



-Topic 605



-SubTopic 25



-Section 50



-Paragraph 2



-Subparagraph (e)



-URI http://asc.fasb.org/extlink&oid=51671369&loc=SL6750900-111635

+ Details

Name:	us-gaap_RevenueRecognitionMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

X

- Definition

Revenue earned during the period from the leasing or otherwise lending to a third party the entity's rights or title to certain property. Royalty revenue is derived from a percentage or stated amount of sales proceeds or revenue generated by the third party using the entity's property. Examples of property from which royalties may be derived include patents and oil and mineral rights.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef



-Publisher FASB



-Name Accounting Standards Codification



-Topic 225



-SubTopic 10



-Section S99



-Paragraph 2



-Subparagraph (SX 210.5-03.1(e))



-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

+ Details

Name:	us-gaap_RoyaltyRevenue
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

X

- Details

Name:	us-gaap_TypeOfArrangementAxis=psdv_EnigmaTherapeuticsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_TypeOfArrangementAxis=psdv_AlimeraSciencesIncMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_TypeOfArrangementAxis=psdv_PfizerCollaborationAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_TypeOfArrangementAxis=psdv_BauschAndLombMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_TypeOfArrangementAxis=psdv_EvaluationAgreementsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type: